VM Pharma LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VM Pharma LLC
Generics Industry At The Forefront In War Against COVID-19 In 2021
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
Purdue CEO: The Year For Transformative M&A Is Here
The private specialty pharma is shopping for a transformative deal or a series of smaller deals that will diversify the company into a new area outside of pain and CNS disorders, CEO Mark Timney says during interview.
Purdue’s Head Of R&D Has Broad Remit To Bring In New Assets
Newly appointed senior VP-R&D Alan Dunton is charged with curing the firm's dependency on pain products.
Deals Shaping The Medical Industry, October 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.